We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+14.89%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$84.5M
AUM Growth
+$408K
Cap. Flow
-$6.67M
Cap. Flow %
-7.9%
Top 10 Hldgs %
59.13%
Holding
48
New
14
Increased
9
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.79M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$4.66M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$3.22M
5
BCAX
Bicara Therapeutics
BCAX
+$2.26M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$5.44M
2
ZLAB icon
Zai Lab
ZLAB
+$5.26M
3
PFE icon
Pfizer
PFE
+$4.97M
4
URGN icon
UroGen Pharma
URGN
+$3.22M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$3.18M

Sector Composition

Rank Sector Weight
1 Healthcare 95.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
1
Cogent Biosciences
COGT
$6.68B
$6.91M 8.19%
962,951
+188,230
+24% +$1.04M
VRNA
2
DELISTED
Verona Pharma
VRNA
$6.52M 7.73%
68,982
-27,839
-29% -$2.06M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$5.1M 6.04%
+40,608
New +$4.66M
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
$4.8M 5.68%
1,286,681
-70,472
-5% -$220K
RARE icon
5
Ultragenyx Pharmaceutical
RARE
$2.88B
$4.74M 5.61%
+130,422
New +$4.7M
ZLAB icon
6
Zai Lab
ZLAB
$2.28B
$4.72M 5.59%
134,895
-160,052
-54% -$5.26M
JAZZ icon
7
Jazz Pharmaceuticals
JAZZ
$15.5B
$4.68M 5.54%
+44,107
New +$4.79M
SLNO
8
PUT
DELISTED
Soleno Therapeutics
SLNO
$4.19M 4.96%
+50,000
New +$3.74M
BBIO icon
9
BridgeBio Pharma
BBIO
$15.9B
$4.18M 4.95%
96,766
-87,156
-47% -$3.17M
TVTX icon
10
Travere Therapeutics
TVTX
$5.27B
$4.09M 4.84%
276,474
+38,987
+16% +$646K
IONS icon
11
Ionis Pharmaceuticals
IONS
$8.99B
$3.88M 4.6%
+98,267
New +$3.22M
ORIC icon
12
Oric Pharmaceuticals
ORIC
$1.11B
$3.5M 4.15%
344,922
-474,272
-58% -$3.18M
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$2.82M 3.34%
33,691
+14,359
+74% +$1.07M
SVRA icon
14
Savara
SVRA
$1.13B
$2.54M 3.01%
1,115,379
+149,176
+15% +$406K
ETNB
15
DELISTED
89bio
ETNB
$2.09M 2.47%
212,377
+103,221
+95% +$855K
CYTK icon
16
Cytokinetics
CYTK
$10.9B
$2.02M 2.39%
61,103
-11,889
-16% -$414K
BCAX
17
Bicara Therapeutics
BCAX
$1.82B
$1.76M 2.09%
+189,699
New +$2.26M
CABA icon
18
Cabaletta Bio
CABA
$461M
$1.61M 1.91%
1,060,764
+601,792
+131% +$938K
TECX
19
Tectonic Therapeutic
TECX
$615M
$1.57M 1.86%
79,058
+28,312
+56% +$574K
INSM icon
20
Insmed
INSM
$23.5B
$1.47M 1.74%
+14,571
New +$1.11M
UTHR icon
21
United Therapeutics
UTHR
$22.7B
$1.4M 1.66%
+4,874
New +$1.46M
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$1.34M 1.58%
47,037
+24,766
+111% +$738K
URGN icon
23
UroGen Pharma
URGN
$1.96B
$1.2M 1.43%
87,912
-335,720
-79% -$3.22M
TARA icon
24
Protara Therapeutics
TARA
$230M
$1.09M 1.29%
360,000
– –
ZBIO
25
Zenas BioPharma
ZBIO
$1.86B
$1.08M 1.28%
111,605
– –
1
2

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Superstring Capital Management held 48 positions worth $84.5M, up 0.49% from $84M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Superstring Capital Management withdrew a net $6.67M in Q2 2025, closing 12 positions and reducing 9 holdings. Its most notable exit was Legend Biotech, an estimated $5.44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Jazz Pharmaceuticals worth $4.68M.

  • Superstring Capital Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 44,107 shares worth $4.68M.
  • Superstring Capital Management added most to Soleno Therapeutics in Q2 2025, an estimated $1.07M increase.
  • Superstring Capital Management's biggest Q2 2025 reduction was Zai Lab, cutting an estimated $5.26M.
  • Superstring Capital Management fully exited Legend Biotech in Q2 2025, selling an estimated $5.44M.
  • Superstring Capital Management's ten largest holdings make up 59% of its $84.5M portfolio in Q2 2025.
  • Superstring Capital Management opened 14 new positions and closed 12 in Q2 2025.
  • Superstring Capital Management's portfolio value rose 0.49% quarter-over-quarter to $84.5M.

Based on Superstring Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.